Pro Speaker

Date 01 October 2012
Event ESMO Congress 2012
Session EGFR inhibitors are the best choice for the first line treatment of EGFR mutated lung adenocarcinoma patients
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Tony Mok
Authors T.S.K. Mok
  • Dept. Of Clinical Oncology, Chinese University of Hong Kong Prince of Wales Hospital, - - Hong Kong/CN